JF - European Respiratory Journal JO - Eur Respir J SP - 980 LP - 985 DO - 10.1183/09031936.06.00125705 VL - 28 IS - 5 AU - Chiang, C-Y。欧裕，M-C。陈志强，陈志强。黄友，R-M。欧旭。李国栋，李国栋，李国栋。Y1 - 2006/11/01 UR - //www.qdcxjkg.com/content/28/5/980.abstract N2 -在台湾台北进行了一项回顾性研究，以确定与肺部耐多药结核病(MDR-TB)结局相关的因素。所有1992-1996年在转诊中心新诊断为肺部耐多药结核的患者被纳入研究，并确定他们在随后6年的预后。共确诊299例患者，其中男性215例(71.9%)，女性84例(28.1%)，平均年龄47.3岁。患者平均接受3.7种有效药物。 Out of the 299 patients, 153 (51.2%) were cured, 31 (10.4%) failed, 28 (9.4%) died and 87 (29.1%) defaulted. Of the 125 patients receiving second-line drugs with ofloxacin, 74 (59.2%) were cured. Those who received ofloxacin had a lower risk of relapse than those receiving only first-line drugs (hazard ratio (HR) 0.16, 95% confidence interval (CI) 0.03–0.81) and a lower risk of TB-related death than those receiving second-line drugs but not ofloxacin (adjusted HR 0.50, 95% CI 0.31–0.82). In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. The utility of new-generation fluoroquinolones, such as moxifloxacin, in the treatment of multidrug-resistant tuberculosis needs to be evaluated. Default from treatment is a major challenge in the treatment of multidrug-resistant tuberculosis. ER -